Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Erectile Dysfunction Might Be Associated With Chronic Periodontal Disease: Two Ends Of The Cardiovascular Spectrum
UroToday.com - Together with Drs. Heruti, Bechor, Justo and Galor, we studied 815 Israeli male adults of whom 305 had complete data and were included in the statistical analysis. In the analyzed population, 2.1% of people without erectile dysfunction (ED) had advanced periodontal disease (defined as recession of periodontal bone of 6 mm or more) in comparison to 9.8% of the mild ED and 15.8% of the moderate/severe ED populations, respectively. However, due to the relatively small groups, we could not present the odds ratio. We are now planning a large-scale study to further establish the association between the two conditions.

Agency Publishes 2012 Salt Reduction Targets
As part of its continued drive to reduce people"s risk of developing coronary heart disease, the Food Standards Agency has today published revised, voluntary salt reduction targets for industry to meet by 2012.
News of the day
Typhoid Vaccine Effectively Prevents Disease In Children, Study Finds
"A typhoid vaccine proved effective in the slums of India, where it not only helped prevent infection in children who received it, but also those in close contact who were unvaccinated," according to a New England Journal of Medicine study published on Thursday, the AP/Washington Post reports (Chang, 7/22).
Health Insurance

Amarillo Biosciences Reaches Enrollment Goal In Australian Influenza Phase 2 Clinical Trial

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) announced that it has reached full enrollment in a Phase 2 clinical study of the company"s oral interferon product at the University of Western Australia located in Perth. A total of 200 healthy volunteers meeting all eligibility criteria have been enrolled to 16 weeks of treatment with oral interferon or matching placebo. The double-blind clinical trial being conducted by Dr. Manfred Beilharz and colleagues is expected to show that lozenges containing a low dose of interferon-alpha can prevent infection or reduce the severity of infection with influenza and other common respiratory viruses when taken once a day during a typical winter cold/flu season. Final study results are expected to be available before the end of the year. Amarillo Biosciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009